Summary
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process requires cooperation from industry, academic researchers, advocacy groups, and patients as well as their caregivers and families. In this white paper, we look at the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these barriers by applying a multi-stakeholder collaborative approach to drug development.
Register to download
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
You may also be interested in:
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Blog
International Nurses Day 2020: Former Nurses Share Experiences on the Frontlines
As part of our contribution to International Nurses Day, we spoke with a few of our 2,300 PRA employees with nursing backgrounds. They share what…
Case Study
Achieving Challenging Recruitment Goals and Timelines in a Pediatric Type 2 Diabetes Study
Recruiting pediatric patients for type 2 diabetes mellitus (T2DM) studies is extremely challenging. Patients are difficult to identify and often face…